PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?

Massimo R. Mannarino, Amirhossein Sahebkar, Vanessa Bianconi, Maria Corina Serban, Maciej Banach, Matteo Pirro

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

The serine protease proprotein convertase subtilisin/kexin type 9 (PCSK9) modulates the levels of low-density lipoprotein cholesterol and cardiovascular risk. Potential risks of adverse neurological effects of intensive lipid-lowering treatment have been hypothesized, as cholesterol is a component of the central nervous system. Moreover, several observations suggest that PCSK9 might play a role in neurogenesis, neuronal migration and apoptosis. In rodents, increased expression of PCSK9 has been detected in specific areas of the central nervous system during embryonic development; also, PCSK9 modulates low-density lipoprotein receptor levels in the ischemic brain areas. Despite a putative participation of PCSK9 in nervous system physiology, the absence of PCSK9 in knockout mice or in humans with loss-of-function mutations of PCSK9 gene has not been linked to neurological alterations. In recent years, some concerns have been raised about the potential neurological side effects of cholesterol-lowering treatments and, more specifically of PCSK9 inhibitors. In this review, the evidence regarding the function of PCSK9 in neuron differentiation, apoptosis, and migration and in nervous system development and latest clinical trials evaluating the effects of PCSK9 inhibitors on neurocognitive function will be described.

Original languageEnglish
Pages (from-to)1123-1132
Number of pages10
JournalJournal of Clinical Lipidology
Volume12
Issue number5
DOIs
Publication statusPublished - 1 Sep 2018

Fingerprint

Nervous System Physiological Phenomena
Central Nervous System
Cholesterol
Proprotein Convertase 9
Apoptosis
LDL Receptors
Neurogenesis
Serine Proteases
Knockout Mice
LDL Cholesterol
Nervous System
Embryonic Development
Rodentia
Clinical Trials
Lipids
Neurons
Mutation
Brain
Genes

Cite this

Mannarino, Massimo R. ; Sahebkar, Amirhossein ; Bianconi, Vanessa ; Serban, Maria Corina ; Banach, Maciej ; Pirro, Matteo. / PCSK9 and neurocognitive function : Should it be still an issue after FOURIER and EBBINGHAUS results?. In: Journal of Clinical Lipidology. 2018 ; Vol. 12, No. 5. pp. 1123-1132.
@article{bcc373dedde146d483715c294c0ed6b3,
title = "PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?",
abstract = "The serine protease proprotein convertase subtilisin/kexin type 9 (PCSK9) modulates the levels of low-density lipoprotein cholesterol and cardiovascular risk. Potential risks of adverse neurological effects of intensive lipid-lowering treatment have been hypothesized, as cholesterol is a component of the central nervous system. Moreover, several observations suggest that PCSK9 might play a role in neurogenesis, neuronal migration and apoptosis. In rodents, increased expression of PCSK9 has been detected in specific areas of the central nervous system during embryonic development; also, PCSK9 modulates low-density lipoprotein receptor levels in the ischemic brain areas. Despite a putative participation of PCSK9 in nervous system physiology, the absence of PCSK9 in knockout mice or in humans with loss-of-function mutations of PCSK9 gene has not been linked to neurological alterations. In recent years, some concerns have been raised about the potential neurological side effects of cholesterol-lowering treatments and, more specifically of PCSK9 inhibitors. In this review, the evidence regarding the function of PCSK9 in neuron differentiation, apoptosis, and migration and in nervous system development and latest clinical trials evaluating the effects of PCSK9 inhibitors on neurocognitive function will be described.",
keywords = "Brain, Cholesterol, Cholesterol-lowering treatment, Neurocognitive function, PCSK9, PCSK9 inhibitors",
author = "Mannarino, {Massimo R.} and Amirhossein Sahebkar and Vanessa Bianconi and Serban, {Maria Corina} and Maciej Banach and Matteo Pirro",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.jacl.2018.05.012",
language = "English",
volume = "12",
pages = "1123--1132",
journal = "Journal of Clinical Lipidology",
issn = "1876-4789",
publisher = "Academic Press",
number = "5",

}

PCSK9 and neurocognitive function : Should it be still an issue after FOURIER and EBBINGHAUS results? / Mannarino, Massimo R.; Sahebkar, Amirhossein; Bianconi, Vanessa; Serban, Maria Corina; Banach, Maciej; Pirro, Matteo.

In: Journal of Clinical Lipidology, Vol. 12, No. 5, 01.09.2018, p. 1123-1132.

Research output: Contribution to journalReview article

TY - JOUR

T1 - PCSK9 and neurocognitive function

T2 - Should it be still an issue after FOURIER and EBBINGHAUS results?

AU - Mannarino, Massimo R.

AU - Sahebkar, Amirhossein

AU - Bianconi, Vanessa

AU - Serban, Maria Corina

AU - Banach, Maciej

AU - Pirro, Matteo

PY - 2018/9/1

Y1 - 2018/9/1

N2 - The serine protease proprotein convertase subtilisin/kexin type 9 (PCSK9) modulates the levels of low-density lipoprotein cholesterol and cardiovascular risk. Potential risks of adverse neurological effects of intensive lipid-lowering treatment have been hypothesized, as cholesterol is a component of the central nervous system. Moreover, several observations suggest that PCSK9 might play a role in neurogenesis, neuronal migration and apoptosis. In rodents, increased expression of PCSK9 has been detected in specific areas of the central nervous system during embryonic development; also, PCSK9 modulates low-density lipoprotein receptor levels in the ischemic brain areas. Despite a putative participation of PCSK9 in nervous system physiology, the absence of PCSK9 in knockout mice or in humans with loss-of-function mutations of PCSK9 gene has not been linked to neurological alterations. In recent years, some concerns have been raised about the potential neurological side effects of cholesterol-lowering treatments and, more specifically of PCSK9 inhibitors. In this review, the evidence regarding the function of PCSK9 in neuron differentiation, apoptosis, and migration and in nervous system development and latest clinical trials evaluating the effects of PCSK9 inhibitors on neurocognitive function will be described.

AB - The serine protease proprotein convertase subtilisin/kexin type 9 (PCSK9) modulates the levels of low-density lipoprotein cholesterol and cardiovascular risk. Potential risks of adverse neurological effects of intensive lipid-lowering treatment have been hypothesized, as cholesterol is a component of the central nervous system. Moreover, several observations suggest that PCSK9 might play a role in neurogenesis, neuronal migration and apoptosis. In rodents, increased expression of PCSK9 has been detected in specific areas of the central nervous system during embryonic development; also, PCSK9 modulates low-density lipoprotein receptor levels in the ischemic brain areas. Despite a putative participation of PCSK9 in nervous system physiology, the absence of PCSK9 in knockout mice or in humans with loss-of-function mutations of PCSK9 gene has not been linked to neurological alterations. In recent years, some concerns have been raised about the potential neurological side effects of cholesterol-lowering treatments and, more specifically of PCSK9 inhibitors. In this review, the evidence regarding the function of PCSK9 in neuron differentiation, apoptosis, and migration and in nervous system development and latest clinical trials evaluating the effects of PCSK9 inhibitors on neurocognitive function will be described.

KW - Brain

KW - Cholesterol

KW - Cholesterol-lowering treatment

KW - Neurocognitive function

KW - PCSK9

KW - PCSK9 inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85049072743&partnerID=8YFLogxK

U2 - 10.1016/j.jacl.2018.05.012

DO - 10.1016/j.jacl.2018.05.012

M3 - Review article

VL - 12

SP - 1123

EP - 1132

JO - Journal of Clinical Lipidology

JF - Journal of Clinical Lipidology

SN - 1876-4789

IS - 5

ER -